Skip to main content
logo
Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
135.03
-0.16 (-0.12%)
At close: Dec 16, 2025, 4:00 PM EST
133.85
-1.18 (-0.87%)
After-hours: Dec 16, 2025, 7:07 PM EST

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Innovative Medicines Revenue
54.35B50.32B
Log In
Log In
Log In
Upgrade
Sandoz Revenue
--
Log In
Log In
Log In
Upgrade
Revenue (Other)
2.02B1.41B
Log In
Log In
Log In
Upgrade
Revenue (Total)
56.37B51.72B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
United States Revenue (Post-Q2 2023 Reporting)
24.00B21.15B
Log In
Log In
Log In
Upgrade
Europe Revenue (Post-Q2 2023 Reporting)
16.29B15.56B
Log In
Log In
Log In
Upgrade
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)
10.46B10.02B
Log In
Log In
Log In
Upgrade
Canada and Latin America Revenue (Post-Q2 2023 Reporting)
3.60B3.59B
Log In
Log In
Log In
Upgrade
Revenue (Other)
2.02B1.41B
Log In
Log In
Log In
Upgrade
Revenue (Total)
56.37B51.72B
Log In
Log In
Log In
Upgrade

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Europe Revenue (Pre-Q3 2023 Reporting)
--
Log In
Log In
Log In
Upgrade
United States Revenue (Pre-Q3 2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Canada and Latin America Revenue (Pre-Q3 2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Revenue (Total)
56.37B51.72B
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Cardiovascular, Renal And Metabolic Revenue
9.76B8.58B
Log In
Log In
Log In
Upgrade
Immunology Revenue
9.98B9.29B
Log In
Log In
Log In
Upgrade
Neuroscience Revenue
5.66B4.75B
Log In
Log In
Log In
Upgrade
Oncology Revenue
16.51B14.74B
Log In
Log In
Log In
Upgrade
Established Brands Revenue
12.45B12.96B
Log In
Log In
Log In
Upgrade
Revenue (Total)
56.37B51.72B
Log In
Log In
Log In
Upgrade

Gross Profit

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Innovative Medicines Gross Profit
--
Log In
Log In
Log In
Upgrade
Sandoz Gross Profit
--
Log In
Log In
Log In
Upgrade
Corporate Gross Profit
--
Log In
Log In
Log In
Upgrade
Gross Profit (Total)
42.96B38.90B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Innovative Medicines Operating Profit
--
Log In
Log In
Log In
Upgrade
Sandoz Operating Profit
--
Log In
Log In
Log In
Upgrade
Corporate Operating Profit
--
Log In
Log In
Log In
Upgrade
Operating Income (Total)
17.56B14.54B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Cosentyx Revenue
6.46B6.14B
Log In
Log In
Log In
Upgrade
Gilenya Revenue
-552.00M
Log In
Log In
Log In
Upgrade
Entresto Revenue
8.68B7.82B
Log In
Log In
Log In
Upgrade
Tasigna Revenue
1.34B1.67B
Log In
Log In
Log In
Upgrade
Lucentis Revenue
720.00M1.04B
Log In
Log In
Log In
Upgrade
Updated Oct 28, 2025. Data Source: Fiscal.ai.